Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM

Phase 1

Terminated

• Conditions: Glioblastoma Multiforme; Analgesics; Peripheral Nervous System Agents; Physiological Effects of Drugs; Analgesics, Non-narcotic; Astrocytoma, Grade IV; Giant Cell Glioblastoma; Cyclophosphamide; Antiviral Agents; Immunosuppressive Agents

• Registration Number: NCT04489420
• Lead Sponsor: Celularity Incorporated

Brief Summary

This study will find the maximum safe dose (MSD) or maximum tolerated dose (MTD) of CYNK-001 which are NK cells derived from human placental CD34+ cells and culture-expanded. CYNK-001 cells will be given after lymphodepleting chemotherapy for the systemic cohort (IV) (intravenous). The intratumoral cohort (IT) will not be giving lymphodepletion. The safety of this treatment will be evaluated, and researchers want to learn if NK cells will help in treating recurrent glioblastoma multiforme.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2020-07-22
• Study First Submitted QC: 2020-07-24
• Study First Posted: 2020-07-28
• Study Start: 2020-10-01
• Primary Completion: 2021-08-10
• Study Completion: 2021-08-10
• Status Verified: 2022-08
• Last Update Submitted: 2022-08-09
• Last Update Posted: 2022-08-10

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: 3

Inclusion Criteria

1. Histologically confirmed glioblastoma multiforme (GBM) and are at first or second relapse.

2. ≥ 18 years of age

3. Have measurable disease of at least one solitary lesion with a dimension between 1 cm and 5 cm according to RANO

4. Karnofsky performance status (KPS) ≥ 60

5. Adequate organ function defined by laboratory values as follows: Creatinine < 140 µmol/L (1.6 mg/dL); if borderline, the creatinine clearance ≥40 mL/min, Bilirubin < 20% above the upper limit of normal, AST and ALT ≤ 2.5 the upper limit of normal.

6. Absolute Neutrophil count baseline (ANC) ≥1500 cells/uL, Hemoglobin baseline ≥ 9.0 g/dL and Platelets baseline ≥ 100,000 cells/uL prior to the start of study treatment.

7. Female of childbearing potential (FCBP) must not be pregnant and agree to not becoming pregnant for at least 42 days following the start of the treatment.

8. Patients with HIV/AIDs are eligible if they have not had an opportunistic infection within the past 12 months

9. Patients with chronic HBV infection or patients with current or a history of HCV infection are allowed if:

   1. have an HBV viral load below the limit of quantification and be on viral suppressive therapy
   2. have current HCV infection, they should be on concurrent HCV treatment and the HCV viral load must be below the limit of quantification
   3. have a history of HCV infection should have completed curative antiviral treatment and require HCV viral load below the limit of quantification

Exclusion Criteria

1. Had prior radiation therapy within 12 weeks of screening MRI unless there is unequivocal histological confirmation of tumor progression
2. Subjects on growth factors therapy with less than 4 weeks washout period (for short-acting growth factors, such as G-CSF, GM-CSF 5-day wash-out for longer-acting factors (such as Neulasta) 10 days
3. Radiotherapy, chemotherapy, or other investigational agents within 4 weeks
4. Prior cellular or gene therapy at any time
5. Clinical or laboratory signs for immunodeficiency or under immunosuppressive medication or steroids greater than15 mg prednisone or equivalent per day
6. History of malignancy, other than GBM, unless the subject has been free of disease for > 3 years from the date of signing the ICF. Exceptions include the following noninvasive malignancies: basal cell carcinoma of the skin, squamous cell carcinoma of the skin, carcinoma in situ of the cervix, carcinoma in situ of the breast, Incidental histological finding of prostate cancer (TNM stage of T1a or T1b)
7. Active autoimmune disease other than controlled connective tissue disorder or those who are not on active therapy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Primary Outcome Measures

Name	Time	Method
Number of Participants who experienced a Dose-Limiting Toxicity (DLT)	Day 42	Defined as the maximum dose safely administered intravenously or Intratumoral for the treatment of patients with GBM.
Adverse Events (AEs)	1 year	Defined as the number and Severity of Adverse Events

Secondary Outcome Measures

Name	Time	Method
Overall Response Rate	1 year	Defined as the proportion of subjects with best overall response of either complete response (CR) or partial response (PR)
Progression-free survival	1year	Defined as date of the first CYNK-001 infusion to the date of disease progression per RANO Response Criteria or death (regardless of cause of death), whichever comes first
Time to porgression	1year	Defined as the date of the first CYNK-001 infusion to the date of disease progression per RANO Response Criteria, with deaths from causes other than progression censored
Duration of Response Rate	1year	Defined as duration from first observation of partial response (PR) or better to the date of disease progression per RANO criteria
Overall Survival	1year	Defined as the date of the first CYNK-001 infusion to the date of death

Trial Locations

Locations (1)

The Univeristy of Texas MD ANderson Cancer Center; 🇺🇸 Houston, Texas, United States